1![Visterra Awarded CARB-X Contract to Advance Development of VIS705 – VIS705 is Visterra’s Novel Antibody-Drug Conjugate Candidate for the Treatment of Deadly Pseudomonas Bacterial Infections – – Contract Valued at Visterra Awarded CARB-X Contract to Advance Development of VIS705 – VIS705 is Visterra’s Novel Antibody-Drug Conjugate Candidate for the Treatment of Deadly Pseudomonas Bacterial Infections – – Contract Valued at](https://www.pdfsearch.io/img/406a48c5997bbb5532a0ad6b46bdcbd1.jpg) | Add to Reading ListSource URL: visterrainc.comLanguage: English - Date: 2017-10-03 19:39:52
|
---|
2![Visterra Awarded CARB-X Contract to Advance Development of VIS705 – VIS705 is Visterra’s Novel Antibody-Drug Conjugate Candidate for the Treatment of Deadly Pseudomonas Bacterial Infections – – Contract Valued at Visterra Awarded CARB-X Contract to Advance Development of VIS705 – VIS705 is Visterra’s Novel Antibody-Drug Conjugate Candidate for the Treatment of Deadly Pseudomonas Bacterial Infections – – Contract Valued at](https://www.pdfsearch.io/img/8a5afa54e164b9074e6ed5e572175e0d.jpg) | Add to Reading ListSource URL: www.visterrainc.comLanguage: English - Date: 2017-10-03 19:39:52
|
---|
3![OUTSOURCING Highly potent market growth Highly potent small-molecule and biologic drugs are typically considered to be those APIs that have an occupational OUTSOURCING Highly potent market growth Highly potent small-molecule and biologic drugs are typically considered to be those APIs that have an occupational](https://www.pdfsearch.io/img/af14136d1e122c5a723a837ee4f7ebcd.jpg) | Add to Reading ListSource URL: www.fermion.fiLanguage: English - Date: 2016-04-07 08:11:40
|
---|
4![FAKULTÄT FÜR CHEMIE Einladung zum Vortrag von __________________________________________________________________________ Dr. Gonçalo Bernardes FAKULTÄT FÜR CHEMIE Einladung zum Vortrag von __________________________________________________________________________ Dr. Gonçalo Bernardes](https://www.pdfsearch.io/img/daf0516ad23050f77c368cab34557ccb.jpg) | Add to Reading ListSource URL: chemie.univie.ac.atLanguage: English - Date: 2016-03-10 06:54:20
|
---|
5![Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 217 Pharmacometric Models for Antibody Drug Conjugates and Taxanes in HER2+ and HER2Breast Cancer Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 217 Pharmacometric Models for Antibody Drug Conjugates and Taxanes in HER2+ and HER2Breast Cancer](https://www.pdfsearch.io/img/0bb5a6f335ec06fd3ea503df251c6c7b.jpg) | Add to Reading ListSource URL: uu.diva-portal.orgLanguage: English - Date: 2016-05-25 07:51:34
|
---|
6![[ Industry Watch ] JAPAN Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Daiichi Sankyo [ Industry Watch ] JAPAN Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Daiichi Sankyo](https://www.pdfsearch.io/img/61e40dc8e7847afa883afa314995ffcd.jpg) | Add to Reading ListSource URL: www.asiabiotech.comLanguage: English - Date: 2008-08-21 23:20:14
|
---|
7![Diamond Analytics Application Note: DA1018-A FLARE Wide Pore C18 Column: Separation of Antibody Drug Conjugate (ADC) Digested Sample Brentuximab-Vedotin was digested with endoproteinase Lys-C Diamond Analytics Application Note: DA1018-A FLARE Wide Pore C18 Column: Separation of Antibody Drug Conjugate (ADC) Digested Sample Brentuximab-Vedotin was digested with endoproteinase Lys-C](https://www.pdfsearch.io/img/bb8d745ea643905885426e879286efee.jpg) | Add to Reading ListSource URL: www.diamond-analytics.com- Date: 2015-04-02 20:08:15
|
---|
8![Award ID: DP150039 Project Title: Armada Pharmaceuticals Inc. New Company Formation for Development of Anti-Cancer Antibody-Drug Conjugate Therapeutics Award Mechanism: Award ID: DP150039 Project Title: Armada Pharmaceuticals Inc. New Company Formation for Development of Anti-Cancer Antibody-Drug Conjugate Therapeutics Award Mechanism:](https://www.pdfsearch.io/img/709a1bac2c72b5f2128a760350902b9c.jpg) | Add to Reading ListSource URL: www.cprit.state.tx.usLanguage: English - Date: 2015-03-24 12:30:06
|
---|
9![The team at Cerulean (NASDAQ: CERU) is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting™ Platform to create a portfolio of nanoparticle-drug conjugates (NDCs) designe The team at Cerulean (NASDAQ: CERU) is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting™ Platform to create a portfolio of nanoparticle-drug conjugates (NDCs) designe](https://www.pdfsearch.io/img/0c74038491851f27d378821a07454981.jpg) | Add to Reading ListSource URL: www.ceruleanrx.comLanguage: English - Date: 2015-06-01 11:12:23
|
---|
10![Draft Labeling Text - Redline, 2014Oct23 Draft Labeling Text - Redline, 2014Oct23](https://www.pdfsearch.io/img/08c8884a75745cdf5cee96667792ac1e.jpg) | Add to Reading ListSource URL: www.seattlegenetics.comLanguage: English - Date: 2015-02-23 11:26:31
|
---|